mide, they observed a significant decrease in total CD34 þ cells per kg, average daily yield, day 1 yield and an increased number of phereses were required compared to historical controls treated with dexamethasone alone, thalidomide-dexamethasone or vincristine, adriamycin and dexamethasone chemotherapy. The decrease in PBSC yield correlated with the length of lenalidomide therapy. Regardless, neutrophil and platelet engraftments post-transplant were similar. They recommended PBSC collection be completed within 6 months of initiation of lenalidomide therapy to minimize this decreased yield.
We confirm the observation of lower PBSC yield after lenalidomide induction therapy. Data were pooled from three centers from patients who had received lenalidomide induction therapy followed by PBSC mobilization. All patients received G-CSF 10 mg kg À1 for 4 days, except for patients 1-8 who were mobilized with 7.5 mcg kg À1 G-CSF and 7.5 mg kg À1 GM-CSF for 5 days as indicated in Table 1 .
Twelve of 28 patients (43%) failed to collect sufficient cells for even one transplant (o2 Â 10 6 CD34 þ cells per kg). It should be noted that three patients also failed to mobilize sufficient stem cells when treated with the CXCR4 inhibitor AMD3100 plus G-CSF on a compassionate use protocol. These patients subsequently had successful mobilization following cyclophosphamide chemotherapy. Similar to the Mayo Clinic observations, for patients who did mobilize X2 Â 10 6 CD34 þ cells per kg, engraftment kinetics were comparable to patients treated with other induction regimens.
Our data mirrored those of Kumar et al. 4 in several aspects. After lenalidomide therapy, there was a decrease in the total number of CD34 þ cells per kg, day 1 collection and the total number of days required to collect sufficient CD34 þ cells compared to chemotherapy and/or bortezomib induction therapy 3 (data not shown). Our data differed from those of Kumar et al. 4 regarding the correlation of the number of cycles of lenalidomide therapy and subsequent PBSC mobilization. They reported no mobilization failures in patients who had less than six cycles of lenalidomide. In contrast, 6 of 12 of our failures had received five or less cycles of lenalidomide. Furthermore, unlike their observations, the length of time of lenalidomide therapy did not clearly correlate with the number of CD34 þ cells obtained. Thus, the optimal time to mobilize CD34 þ cells is not clear. On the basis of these data, we recommend cyclophosphamide for mobilization of patients with prior lenalidomide exposure. We would like to commend Professor Mazumder et al.
A
1 for presenting additional data that confirm our initial observation of decreased stem mobilization following the use of lenalidomidebased therapies for newly diagnosed myeloma. 2 The rate of peripheral blood stem cell collection failure in this report is higher than what we have observed in our analysis of all patients with myeloma undergoing an attempt at stem collection. To some extent, this probably reflects the total number of apheresis that the patients were subjected to. The median number of collections from patients who had prior lenalidomide was five in our study compared to three in the current report. Also, it is not clear whether every patient who received lenalidomide-based initial therapy, who came to stem collection at the three institutions, were included in the study. Irrespective of the differences in the two studies, both convey the same message.
Physicians and patients should be aware of the potential for mobilization failures when lenalidomide is used for initial therapy. Whether this is a function of one or more of the factors such as older age, longer duration of therapy or interval from the last dose of lenalidomide to initiation of growth factors needs to be further studied in this patient group. Clearly, use of chemotherapy for mobilization is an option in these patients. It is unclear whether we need to adopt this for all the patients, or only use this for rescue in case of initial failure. A longer rest period off lenalidomide (approximately 4 weeks) prior to stem cell mobilization may be helpful, and we have initiated this change at our institution. We believe that once mobilizing agents such as AMD-3100 become available, this issue will be resolved to a large extent. High-dose melphalan followed by autologous stem cell transplant (ASCT) has been a cornerstone of therapy for multiple myeloma (MM) since landmark articles demonstrating clinical benefit were published over 10 years ago. 1 As adequate stem cell collection is a prerequisite for successful ASCT, it was quickly appreciated that prior use of the alkylating agent melphalan resulted in an inability to collect stem cells in approximately 60% of patients who had received more than five cycles of therapy. 2 As a consequence of this observation, the use of lower dose melphalan was abandoned as an induction therapy in patients in whom stem cell transplant was later being considered and was replaced with dexamethasone-based induction regimens. Following the use of dexamethasone alone or in combination with adriamycin and vincristine-based (VAD) chemotherapy, stem cell collection is successful in the vast majority of patients. 3 However, recent positive clinical trial results have prompted a shift in the choice of induction therapy to regimens combining an immunomodulatory drug such as thalidomide, or more recently, lenalidomide with dexamethasone in preference to VAD chemotherapy. 4, 5 Thalidomide is not generally myelosuppressive and in large studies, stem cell collection numbers were only modestly lower than that seen with VAD chemotherapy, with 84% of patients collecting sufficient stem cells for tandem transplant. 6 Promising results on the use of lenalidomide and dexamethasone have resulted in a recommendation for the use of this combination in newly diagnosed patients heading for transplant. 7 However, one recent analysis of stem cell collection following lenalidomide induction indicated that stem cell collection yields are compromised in some patients. 8 We read with interest the paper by Mazumder et al. on the effect of lenalidomide on stem cell mobilization. 9 We report here further evidence for a detrimental effect of lenalidomide on the ability to mobilize stem cells successfully. Specifically, in 9 of 20 (45%) patients who received lenalidomide at our center as induction therapy, a successful stem cell collection (42 Â 10 6 CD34-positive cells kg À1 ) following granulocyte colony-stimulating factor (G-CSF) 10 mg kg À1 alone could not be obtained or was severely comprised at first collection attempt by prior lenalidomide use.
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We performed a retrospective chart review after the clinical observation of difficulty in mobilizing stem cells in patients treated with lenalidomide and dexamethasone was made. MM patients undergoing stem cell collection between January 2005 and October 2007 were analyzed for type and duration of induction therapy, collection efficacy and engraftment in patients who went to transplant. All data were extracted from patient medical records and from our transplant database. The study was approved by the Mayo Foundation Institutional Review Board.
Sixty-one patients were identified who underwent stem cell mobilization using G-CSF at 10 mg kg
À1
, with collection beginning on day 5. Of the 61 patients, 20 underwent induction therapy with lenalidomide and dexamethasone and the remaining 41 patients received other induction therapies such as thalidomide and dexamethasone, VAD-or bortezomibcontaining regimens. Baseline characteristics between the two groups were statistically identical for gender, age, hemoglobin, platelets, creatinine, calcium, b-2-microglobulin, C-reactive protein, isotype, monoclonal protein level and presence of lytic bone disease and bone marrow plasma cell percentage (not shown). Baseline mean total leukocyte count was slightly lower in the lenalidomide-treated group (mean 5.1 versus 6.1; P ¼ 0.032 for Wilcoxon rank sum test). All the patients underwent collection with processing of five total blood volumes, using a mixture of heparin citrate (6000 U heparin l À1 acid citrate dextrose solution A (ACDA)). Patient details and therapy leading up to time of transplantation are noted under Supplementary data. The selected criteria for failure of first and total stem cell collection were defined as:
Collection not attempted as peripheral blood CD34
þ cell count consistently o10 cells ml In 41 patients who received thalidomide and dexamethasone, VAD chemotherapy or a bortezomib-based regimen as induction, only three patients (7.3%) failed to achieve successful first collection using the criteria above. However, in the 20 patients who initially received therapy with lenalidomide, stem cell collection was unsuccessful at the first attempt in 9 patients (45%), a statistically significant difference (P ¼ 0.0011 for Fisher's exact test). Furthermore, stem cell numbers collected were severely compromised even in those patients who had sufficient cells to proceed to transplant, with 13 of 20 (65%) failing to collect our target of at least 5 Â 10 6 CD34 þ cells per kg body weight ( Table 1) . The mean peripheral blood CD34 þ cell count (14.0 versus 28.9 cells ml À1 ; P ¼ 0.0002 for Wilcoxon rank sum test) and mean total CD34 þ cells collected (5.1 Â 10 6 versus 7.4 Â 10 6 cells kg À1 ; P ¼ 0.0025 for Wilcoxon rank sum test) were significantly lower in the patients who received lenalidomide versus other induction therapies. The mean number of days of collection (3.6 versus 2.8 days; P ¼ 0.07 for Wilcoxon rank sum test) was greater in the patients who received lenalidomide, although this was not statistically significant ( Figure 1 ).
